SPRO Spero Therapeutics

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update.

To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this and request a return call with passcode 0605709. The audio webcast can be accessed live on this and also on the “Investor Relations” page of the Spero Corporate Website at . The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit

Spero Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics



Spero Media Inquiries:



EN
05/08/2025

Underlying

SPROSpero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spero Therapeutics

 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Second Quarter 2025 Operating Results and...

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company’s cu...

August 12, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report Second Quarter 2025 Financial Results and...

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the ca...

August 5, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipen...

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero’...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces First Quarter 2025 Operating Results and ...

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on iden...

May 13, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report First Quarter 2025 Financial Results and ...

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsS...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch